Inhibiting the crosstalk between PD-1/PD-L1 thus allows the body to resume its natural T cell-mediated anti-tumor inflammatory response in the context of tumor cells gaining peripheral tolerance inappropriately. Here, PDCD1 is linked to neoplasm.